trending Market Intelligence /marketintelligence/en/news-insights/trending/es-s7ndbw2bnds2iezxlba2 content esgSubNav
In This List

Gene editing execs talk CRISPR potential; 2018 healthcare IPOs top 2017 proceeds

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Gene editing execs talk CRISPR potential; 2018 healthcare IPOs top 2017 proceeds

Here are the editors' top picks for the week ended Oct. 12.

A CRISPR primer: Gene editing company leaders talk tech's potential in humans

What's all the fuss about with Clustered Regularly Interspaced Short Palindromic Repeats? The major CRISPR companies' executives explain how the tool works and what it is being leveraged for ahead of the first company-sponsored human trial.

Global healthcare IPOs fetch $19.18B year-to-date, topping 2017 proceeds

Gross proceeds from global healthcare IPOs year-to-date in 2018 exceeded amounts raised last year, according to data compiled by S&P Global Market Intelligence.

New study links IVF process itself to higher chance of multiple births

The largest study ever of multiple pregnancies after a single embryo transfer during IVF has found that using thawed embryos or maturing the fertilized egg in the laboratory before implanting it could increase the risk of multiple births.

Healthcare equipment companies drive M&A activity in Q3

Deals for healthcare equipment companies largely drove M&A activity in the third quarter as companies shored up their core business with acquisitions.

Trevena opioid oliceridine rejected by US FDA panel in close vote

An outside panel of expert advisers to the U.S. Food and Drug Administration declined to recommend approval of Trevena Inc.'s intravenous opioid oliceridine, narrowly voting it down 8 to 7.

AbbVie, Novartis settle Humira biosimilar dispute for 2023 US launch

AbbVie Inc. has agreed to grant Novartis AG generic unit Sandoz a license to market a biosimilar of rheumatoid arthritis drug Humira beginning in 2023, marking an end to a patent lawsuit between the two pharmaceutical companies.

Medtronic disables internet updates for 2 medical devices over hacking concerns

Medtronic plc disabled internet updates on Oct. 11 for two CareLink models after warning doctors about the devices' vulnerability to cyberattacks. The company said there have been no reports of patients being harmed from a cyberattack.

Canadian regulators call for more transparent disclosure from cannabis companies

Just in time for Canada's legalization of marijuana, the Canadian Securities Administrators have asked cannabis companies to improve disclosure processes after a review of 70 companies revealed practices that would not properly inform investors.

Amgen vs. Novartis: Enbrel patent fight will further shape biosimilar law

A biosimilar law fraught with ambiguities will once again be shaped by a fight between Amgen Inc. and Novartis over the autoimmune drug Enbrel.

China adds 17 anti-cancer drugs under national insurance coverage

The State Medical Insurance Administration said in a notice on its website that provincial regulators will come up with detailed rules regarding reimbursement of the drugs.

Novo Nordisk shares slide as competition intensifies in diabetes, hemophilia

Shares in Novo Nordisk A/S continued to slide as investors digested news that Roche Holding AG's rival hemophilia drug Hemlibra received expanded approval on the same day that Eli Lilly and Co. released positive data for its experimental diabetes medicine.

Capitol Checkup: Pro-pharma group revealed; GOP 'pre-existing conditions' zeal

A new pro-brand-name drug industry group revealed who was running the organization, but details about its funding remain unclear; and after years of trying to repeal the Affordable Care Act, some Republicans are now backtracking ahead of elections.